company background image
LQDA

LiquidiaNasdaqCM:LQDA Stock Report

Last Price

US$5.50

Market Cap

US$285.9m

7D

-12.0%

1Y

87.7%

Updated

23 Jan, 2022

Data

Company Financials +
LQDA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

LQDA Stock Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Liquidia
Historical stock prices
Current Share PriceUS$5.50
52 Week HighUS$7.16
52 Week LowUS$2.25
Beta0.24
1 Month Change17.77%
3 Month Change53.20%
1 Year Change87.71%
3 Year Change-63.33%
5 Year Changen/a
Change since IPO-50.45%

Recent News & Updates

Jan 18

Liquidia And United: The Tango Continues

Liquidia's November tentative approval does not end the story. The 30-month stay will last until October 2022, or earlier if the Court decides faster. Liquidia has almost won the battle, but '066 still remains a hurdle.

Shareholder Returns

LQDAUS PharmaceuticalsUS Market
7D-12.0%-2.5%-6.1%
1Y87.7%5.3%4.2%

Return vs Industry: LQDA exceeded the US Pharmaceuticals industry which returned 5.3% over the past year.

Return vs Market: LQDA exceeded the US Market which returned 4.2% over the past year.

Price Volatility

Is LQDA's price volatile compared to industry and market?
LQDA volatility
LQDA Average Weekly Movement12.3%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: LQDA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: LQDA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200451Roger Jeffshttps://www.liquidia.com

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States.

Liquidia Fundamentals Summary

How do Liquidia's earnings and revenue compare to its market cap?
LQDA fundamental statistics
Market CapUS$285.88m
Earnings (TTM)-US$39.10m
Revenue (TTM)US$10.38m

27.5x

P/S Ratio

-7.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LQDA income statement (TTM)
RevenueUS$10.38m
Cost of RevenueUS$2.53m
Gross ProfitUS$7.84m
ExpensesUS$46.95m
Earnings-US$39.10m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.75
Gross Margin75.58%
Net Profit Margin-376.78%
Debt/Equity Ratio14.2%

How did LQDA perform over the long term?

See historical performance and comparison

Valuation

Is Liquidia undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: LQDA ($5.5) is trading below our estimate of fair value ($64.2)

Significantly Below Fair Value: LQDA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: LQDA is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: LQDA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LQDA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LQDA is overvalued based on its PB Ratio (3.9x) compared to the US Pharmaceuticals industry average (2.1x).


Future Growth

How is Liquidia forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

57.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LQDA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LQDA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LQDA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LQDA's revenue (46.7% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: LQDA's revenue (46.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LQDA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Liquidia performed over the past 5 years?

-12.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LQDA is currently unprofitable.

Growing Profit Margin: LQDA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LQDA is unprofitable, and losses have increased over the past 5 years at a rate of 12.4% per year.

Accelerating Growth: Unable to compare LQDA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LQDA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: LQDA has a negative Return on Equity (-53.59%), as it is currently unprofitable.


Financial Health

How is Liquidia's financial position?


Financial Position Analysis

Short Term Liabilities: LQDA's short term assets ($67.5M) exceed its short term liabilities ($7.1M).

Long Term Liabilities: LQDA's short term assets ($67.5M) exceed its long term liabilities ($20.3M).


Debt to Equity History and Analysis

Debt Level: LQDA has more cash than its total debt.

Reducing Debt: Insufficient data to determine if LQDA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LQDA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if LQDA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Liquidia current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LQDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LQDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LQDA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LQDA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LQDA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Roger Jeffs (59 yo)

no data

Tenure

US$89,062

Compensation

Dr. Roger A. Jeffs, Ph D., serves as Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since November 2020 and also serves as its Chief Executive Officer. He serves as Co-Fou...


Leadership Team

Experienced Management: LQDA's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: LQDA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: LQDA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.9%.


Top Shareholders

Company Information

Liquidia Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Liquidia Corporation
  • Ticker: LQDA
  • Exchange: NasdaqCM
  • Founded: 2004
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$285.879m
  • Shares outstanding: 51.98m
  • Website: https://www.liquidia.com

Number of Employees


Location

  • Liquidia Corporation
  • 419 Davis Drive
  • Suite 100
  • Morrisville
  • North Carolina
  • 27560
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:16
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.